Advertisement

[14C]-L-Valine Binding to Post Mortem Frontal Cortex Homogenates in Hepatic Encephalopathy

  • P. Riederer
  • Elisabeth Kienzl
  • K. Jellinger
  • G. Kleinberger

Abstract

In hepatic encephalopathy (HE) the plasma aromatic amino acid (AAA) concentrations are increased, while branched chain amino acid (BCAA) levels are reduced. Increased availability of AAA in particular of tryptophan (TRP) at brain uptake sites will influence brain synthesis and turnover of neurotransmitters like serotonin (5-hydroxytryptamine; 5-HT). In HE increased TRP, 5-HT and 5-hydroxyindole acetic acid (5-HIAA) concentrations and enhanced 5-HT turnover have been demonstrated in human post mortem brain studies with kynurenine synthesis being more pronounced in plasma than in the brain.1 Treatment with BCAA and in particular L-valine (VAL) frequently lead to awakening of patients from hepatic coma2,3 and this effect has been suggested to correlate with normalization of 5-HT disturbances in the brain.1 Corresponding changes in 5-HT receptor activity occur in HE and may be influenced by the administration of VAL. Using radioreceptor ligand binding techniques with 3H-5-HT and 3H-spiro-peridol (R 50–656 as unlabeled ligand to define unspecific binding) it has been shown in human post mortem frontal cortex that 5-HT-1 receptors (labeled by 3H-5-HT) lose binding density with a slight increase in affinity (total specific binding; B: − 58%, KD=−35%) while treatment with VAL normalizes both 5-ET-lmreceptor density (Bmax: −4%) and affinity (KD = 0%) ex vivo. 4These results have been confirmed by in vitro studies using either control tissue or tissue (frontal cortex) from patients dying from severe hepatic failure.

Keywords

Frontal Cortex Hepatic Encephalopathy Aromatic Amino Acid Branch Chain Amino Acid Receptor Density 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. Riederer, P. Kruzik, E. Kienzl, G. Kleinberger, K. Jellinger, and W. Wesemann, Central aminergic function and its disturbbance by hepatic disease: current status of L-valine pharmacotherapy in metabolic coma, in “Transmitter Biochemistry of Human Brain Tissue”, Riederer P., E. Usdin eds.; Macmillan Publ. Ltd.,London-Basingstoke, 143–182 (1981).Google Scholar
  2. 2.
    G. Kleinberger, R. Dudczak, P. Ferenci, H. Pamperl, P. Riederer, and K. Widhalm, Parenteral Ernährung bei schwerer Leberinsuffizienz, Z. Gastroenterol. Suppl. 16: 99 (1980).Google Scholar
  3. 3.
    G. Kleinberger, P. Riederer, P. Ferenci, and H. Binder, Complete parenteral nutrition and intravenous administration of L-valine in hepatic coma, in “Aminosäuren-und Ammoniakstoffwechsel bei Leberinsuffizienz”. E. Holm ed.; Witzstrock, Baden-Baden, Köln, New York, pp. 220–225 (1982).Google Scholar
  4. 4.
    N. Arold, Ph. D. Thesis, Philipps-Universität, Marburg, GFR, (1982).Google Scholar
  5. 5.
    E. Kienzl, P. Riederer, K. Jellinger,and G. K.einberger, Antagonisierung der Ammoniakwirkung auf Serotoninrezeptoren durch L-valin, Leber.Magen.Darm.12 Nr. 5: 179 (1982).Google Scholar
  6. 6.
    P. Riederer, E. Kienzl, K. Jellinger, H. Noller, and G. Klein-berger, General properties of 14C-L-valine-binding to human brain tissue, Journal of Neural Transm. Suppl.in press (1982).Google Scholar
  7. 7.
    M. Rössle, R. Herz, G. Lehmann, M. Luft, and W. Gerok, Therapie der hepatischen Enzephalopathie, Infusionstherapie 9: 256 (1982).Google Scholar
  8. 8.
    M. Weiser, P. Riederer,and G. Kleinberger, Human cerebral free amino acids in hepatic coma, J. Neural. Transm. Suppl. 14: 95 (1978).Google Scholar
  9. 9.
    E. Kienzl, P. Riederer, K. Jellinger, and G. Kleinberger, [4C] -L-valine binding to membranes of the frontal cortex in hepatic encephalopathy, J. Neural. Transm. 55: in press (1982).Google Scholar
  10. 10.
    A. L. Goldberg and M. E. Tischler, Regulatory effects of leucine on carbohydrate and protein metabolism, in ‘Metabolism and Clinical Implications of Branched Chain Amino and Ketoacids“. M. Walser, J. R. Williamson, eds., Elsevier, North Holland, New York, pp. 205–216 (1981).Google Scholar
  11. 11.
    J. Wahren, J. Denis, P. Desurmont, S. Eriksson, J. M. Escoffier, A.P. Gauthier, L. Hagenfeldt, H. Michel, P. Opolon, J.C. Paris,and M. Veyrac, Is i.v. administration of BCAA effective in the treatment of hepatic encephalopathy? A multicenter study. Abstract FC 47, ESPEN Congress, Maastrich, 1981.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • P. Riederer
    • 1
    • 2
  • Elisabeth Kienzl
    • 1
    • 2
  • K. Jellinger
    • 1
    • 2
  • G. Kleinberger
    • 1
    • 2
  1. 1.Ludwig Boltzmann Institute of ClinNeurobiology Lainz-HospitalViennaAustria
  2. 2.Department of Medicine IUniversity School of MedicineViennaAustria

Personalised recommendations